Fresenius Kabi USA has issued a Class I recall for Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, NDC 65219-594-20. According to the recall notice, an internal investigation at the firm found the product to contain glass particulate matter.
Loading...